Alkermes plc Q3 2025 Earnings Recap

ALKS Q3 2025 October 28, 2025

Get alerts when ALKS reports next quarter

Alkermes reported robust third-quarter results, driven by strong product performance and strategic advancements, prompting an increase in 2025 financial guidance.

Earnings Per Share Beat

$0.49 vs $0.42 est.

+16.7% surprise

Revenue Beat

394185000 vs 379887500 est.

+3.8% surprise

Market Reaction

1-Day +4.31%

5-Day +3.3%

30-Day -3.73%

See ALKS alongside your other holdings

Add to your portfolio — free

Key Takeaways

Total revenues reached $394.2 million, with proprietary product sales increasing 16% year-over-year to $317.4 million.
The proposed acquisition of Avadel Pharmaceuticals is expected to enhance Alkermes' position in the sleep medicine market and diversify its product portfolio.
GAAP net income for the quarter was $82.8 million, demonstrating strong profitability alongside a significant gross-to-net benefit from Medicaid utilization.
Research and development expenses rose to $81.7 million, reflecting investment in ongoing and upcoming clinical studies for orexin receptor agonists.
Full-year 2025 guidance increased, underlining confidence in sustained commercial traction and operational execution.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ALKS on AllInvestView.

Previous Q2 2025

Next Q1 2026